547 related articles for article (PubMed ID: 21781227)
21. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
Zhang Y; Won SH; Jiang C; Lee HJ; Jeong SJ; Lee EO; Zhang J; Ye M; Kim SH; Lü J
Pharm Res; 2012 Jun; 29(6):1595-608. PubMed ID: 22281759
[TBL] [Abstract][Full Text] [Related]
22. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
23. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
[TBL] [Abstract][Full Text] [Related]
24. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
25. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
26. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.
Lu L; Schulz H; Wolf DA
BMC Cell Biol; 2002 Aug; 3():22. PubMed ID: 12188931
[TBL] [Abstract][Full Text] [Related]
27. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
29. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
30. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
31. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
Jennbacken K; Gustavsson H; Tesan T; Horn M; Vallbo C; Welén K; Damber JE
Prostate; 2009 Aug; 69(11):1164-75. PubMed ID: 19399749
[TBL] [Abstract][Full Text] [Related]
32. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
33. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
34. The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer.
Chang GT; Jhamai M; van Weerden WM; Jenster G; Brinkmann AO
Endocr Relat Cancer; 2004 Dec; 11(4):815-22. PubMed ID: 15613454
[TBL] [Abstract][Full Text] [Related]
35. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
36. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
37. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population.
Heer R; Robson CN; Shenton BK; Leung HY
J Cell Physiol; 2007 Sep; 212(3):572-8. PubMed ID: 17541959
[TBL] [Abstract][Full Text] [Related]
38. Targeting androgen receptor/Src complex impairs the aggressive phenotype of human fibrosarcoma cells.
Castoria G; Giovannelli P; Di Donato M; Hayashi R; Arra C; Appella E; Auricchio F; Migliaccio A
PLoS One; 2013; 8(10):e76899. PubMed ID: 24130806
[TBL] [Abstract][Full Text] [Related]
39. Control of the proliferation of prostate cancer cells by an androgen and two antiandrogens. Cell specific sets of responses.
Foury O; Nicolas B; Joly-Pharaboz MO; André J
J Steroid Biochem Mol Biol; 1998 Aug; 66(4):235-40. PubMed ID: 9744520
[TBL] [Abstract][Full Text] [Related]
40. Hunterian Lecture. Characterisation of human prostate epithelial progenitor differentiation in response to androgens.
Heer R
Ann R Coll Surg Engl; 2011 Sep; 93(6):424-8. PubMed ID: 21929909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
